Evidence mapPaperPMID 33808241Full record

ReviewInternational journal of molecular sciences2021

Mesenchymal Stem Cells as a Cornerstone in a Galaxy of Intercellular Signals: Basis for a New Era of Medicine.

Silvia Fernández-Francos, Noemi Eiro, Luis A Costa, Sara Escudero-Cernuda, María Luisa Fernández-Sánchez, Francisco J Vizoso

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. AdvancingFrontiers in bioengineering and biotechnology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Regenerative strategies for intervertebral disc degeneration.Journal of orthopaedic translation · 2025
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Silvia Fernández-FrancosResearch Unit, Fundación Hospital de Jove, 33290 Gijón, Spain.ORCID 0000-0003-1937-6078
Noemi EiroResearch Unit, Fundación Hospital de Jove, 33290 Gijón, Spain.ORCID 0000-0001-5840-4807
Luis A CostaResearch Unit, Fundación Hospital de Jove, 33290 Gijón, Spain.ORCID 0000-0001-9171-6706
Sara Escudero-CernudaDepartment of Physical and Analytical Chemistry, Faculty of Chemistry, University of Oviedo, 33006 Oviedo, Spain.
María Luisa Fernández-SánchezDepartment of Physical and Analytical Chemistry, Faculty of Chemistry, University of Oviedo, 33006 Oviedo, Spain.
Francisco J VizosoResearch Unit, Fundación Hospital de Jove, 33290 Gijón, Spain.ORCID 0000-0002-2827-5511
Fundación Hospital de Jove · ESUniversidad de Oviedo · ES

Funding

Instituto de Salud Carlos III PI20/01122
6 · The paper itself

Abstract

Around 40% of the population will suffer at some point in their life a disease involving tissue loss or an inflammatory or autoimmune process that cannot be satisfactorily controlled with current therapies. An alternative for these processes is represented by stem cells and, especially, mesenchymal stem cells (MSC). Numerous preclinical studies have shown MSC to have therapeutic effects in different clinical conditions, probably due to their mesodermal origin. Thereby, MSC appear to play a central role in the control of a galaxy of intercellular signals of anti-inflammatory, regenerative, angiogenic, anti-fibrotic, anti-oxidative stress effects of anti-apoptotic, anti-tumor, or anti-microbial type. This concept forces us to return to the origin of natural physiological processes as a starting point to understand the evolution of MSC therapy in the field of regenerative medicine. These biological effects, demonstrated in countless preclinical studies, justify their first clinical applications, and draw a horizon of new therapeutic strategies. However, several limitations of MSC as cell therapy are recognized, such as safety issues, handling difficulties for therapeutic purposes, and high economic cost. For these reasons, there is an ongoing tendency to consider the use of MSC-derived secretome products as a therapeutic tool, since they reproduce the effects of their parent cells. However, it will be necessary to resolve key aspects, such as the choice of the ideal type of MSC according to their origin for each therapeutic indication and the implementation of new standardized production strategies. Therefore, stem cell science based on an intelligently designed production of MSC and or their derivative products will be able to advance towards an innovative and more personalized medical biotechnology.

Indexed as

AnimalsExosomesHumansMesenchymal Stem CellsMesenchymal Stem Cell TransplantationRegenerative Medicinebioreactorexosomesextracellular vesiclesex vivo MSC modificationsMSC in vitro productionMSC large-scale expansionsecretome

Identifiers

PMID33808241
PMCPMC8036553
OpenAlexW3152024601

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.